Current Report Filing (8-k)
June 01 2018 - 12:06PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event
reported): June 1, 2018
BOSTON THERAPEUTICS, INC.
(Exact name of registrant as specified
in its charter)
Delaware
|
000-54586
|
27-0801073
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(IRS Employer Identification Number)
|
354 Merrimack Street, #4, Lawrence, MA
01843
(Address of principal executive offices)
(zip code)
(603) 935-9799
(Registrant’s telephone number,
including area code)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
☐
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant
is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter)
or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 7.01 – Regulation FD Disclosure
Boston Therapeutics, Inc. (the “Company”)
has updated its investor presentation. This material may be used during discussions with certain investors and is attached as Exhibit
99.1 to this Current Report and is incorporated by reference into this Item 7.01.
The updated presentation is also available
through the Company’s Investor Relations tab at www.bostonti.com. The information in this report is being furnished, not
filed, pursuant to Regulation FD. Accordingly, the information in Items 7.01 and 9.01 of this report will not be incorporated by
reference into any registration statement filed by the Company under the Securities Act of 1933, as amended, unless specifically
identified therein as being incorporated therein by reference.
Item 9.01 Financial Statements
and Exhibits
(c) Exhibits
SIGNATURES
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
BOSTON
THERAPEUTICS, INC.
|
|
|
|
Date: June 1, 2018
|
|
By:
/s/ Carl W. Rausch
|
|
|
Name:
Carl W. Rausch
|
|
|
Title:
Chief Executive Officer
|